Sandoz News and Activities

Sandoz is one of the...

• Forbes Global 2000 (#1319);
• TOB Iconic 10,000.

Sandoz is a company listed under the stock ticker SDZNY (DE).

Sandoz has a direct presence in 17 countries.

Sandoz has 18 subsidiaries including Lek, Sandoz Asia and Sandoz Austria.

View the org chart displaying its 200 main executives

Most searched biographies at Sandoz

• Richard Saynor, Chief Executive Officer
• Shamiram Feinglass, Director
• Yannis Skoufalos, Director

Popular executive movements at Sandoz

• Armin Metzger will join the company as President of Biosimilars Development, Manufacturing and Supply on Apr. 1, 2026  (posted on March 27 2026).
• Sidita Sulejmani, who was Head of HR Strategy and Portfolio Management, is promoted to Head of Human Resources Development  (posted on December 21 2025).

Create your alert
to follow the executive moves at Sandoz.

Sandoz has 1,915 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• AbbVie has announced the acquisition of Apogee Therapeutics  (posted on June 23 2026).
• The new name of Stealth BioTherapeutics is Mighty Therapeutics. (posted on June 19 2026).
• Transcend has announced the acquisition of Otsuka America Pharmaceutical  (posted on June 18 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Tracey Franklin - Chief People and Digital Technology Officer at Moderna
• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly

Learn more about the Pharmaceuticals industry

Press releases by Sandoz

• All News | Sandoz
• Major Novartis investment in Slovenia reinforces commitment to largest Sandoz product and business | Sandoz
• Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe* | Sandoz
• Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued | Sandoz
• Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) | Sandoz
• HEXAL launches Dimethyl fumarate HEXAL® a generic drug for Tecfidera®, in Germany, offering an economically efficient treatment option for the care of adult patients with multiple sclerosis* | Sandoz
• Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA | Sandoz
• Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030 | Sandoz
• Sandoz appoints new Board representative to global AMR Industry Alliance | Sandoz
• Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio | Sandoz
• View more press releases Close

Social media about Sandoz

• Sandoz on Wikipedia, Google News & Yahoo Finance
• Sandoz on LinkedIn, X (Twitter) & YouTube